# Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

> **NCT01442519** · PHASE3 · COMPLETED · sponsor: **University of Rome Tor Vergata** · enrollment: 212 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** bacillus Calmette-Guerin
- **DRUG:** electromotive mitomycin

## Key facts

- **NCT ID:** NCT01442519
- **Lead sponsor:** University of Rome Tor Vergata
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-01
- **Primary completion:** 2002-06
- **Final completion:** 2002-06
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2011-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01442519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01442519, "Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01442519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*